Pharmacodynamics of daptomycin in a murine thigh model of Staphylococcus aureus infection.
about
A novel approach to pharmacodynamic assessment of antimicrobial agents: new insights to dosing regimen design"One-size-fits-all"? Optimizing treatment duration for bacterial infectionsEvaluation of high-dose daptomycin for therapy of experimental Staphylococcus aureus foreign body infection.Single-dose daptomycin pharmacokinetics in chronic haemodialysis patients.Exploring the collaboration between antibiotics and the immune response in the treatment of acute, self-limiting infectionsShort-course gentamicin in combination with daptomycin or vancomycin against Staphylococcus aureus in an in vitro pharmacodynamic model with simulated endocardial vegetations.Impact of burden on granulocyte clearance of bacteria in a mouse thigh infection modelPharmacodynamics of caspofungin in a murine model of systemic candidiasis: importance of persistence of caspofungin in tissues to understanding drug activity.Use of pharmacokinetic and pharmacodynamic principles to determine optimal administration of daptomycin in patients receiving standardized thrice-weekly hemodialysis.Pharmacokinetics and pharmacodynamics of intravenous daptomycin during continuous ambulatory peritoneal dialysis.Pharmacodynamics of oritavancin (LY333328) in a neutropenic-mouse thigh model of Staphylococcus aureus infectionIn vivo pharmacodynamic activity of daptomycinAntibiotic-loaded chitosan film for infection prevention: A preliminary in vitro characterizationEvaluation of two sources of calcium sulfate for a local drug delivery system: a pilot studyDaptomycin.Rapid bactericidal activity of daptomycin against methicillin-resistant and methicillin-susceptible Staphylococcus aureus peritonitis in mice as measured with bioluminescent bacteria.High-dose daptomycin therapy for staphylococcal endocarditis and when to apply it.Influence of morbid obesity on the single-dose pharmacokinetics of daptomycin.Daptomycin - a novel antibiotic against Gram-positive pathogens.Daptomycin versus vancomycin in a methicillin-resistant Staphylococcus aureus endophthalmitis rabbit model: bactericidal effect, safety, and ocular pharmacokinetics.Daptomycin and tigecycline have broader effective dose ranges than vancomycin as prophylaxis against a Staphylococcus aureus surgical implant infection in miceAmikacin Concentrations Predictive of Ototoxicity in Multidrug-Resistant Tuberculosis PatientsEmerging drugs for bacterial urinary tract infections.Update on daptomycin: the first approved lipopeptide antibiotic.Daptomycin pharmacokinetics and pharmacodynamics in a pooled sample of patients receiving thrice-weekly hemodialysisEvaluation of Daptomycin Exposure and Efficacy and Safety Endpoints To Support Risk-versus-Benefit Considerations.Pharmacokinetics and pharmacodynamics of ASP2151, a helicase-primase inhibitor, in a murine model of herpes simplex virus infection.Population pharmacokinetics of daptomycinAnalysis of daptomycin efficacy and breakpoint standards in a murine model of Enterococcus faecalis and Enterococcus faecium renal infectionDaptomycin: a review 4 years after first approval.Protein binding of antimicrobials: methods for quantification and for investigation of its impact on bacterial killing.Intradialytic administration of daptomycin in end stage renal disease patients on hemodialysis.Daptomycin in bone and joint infections: a review of the literature.Pharmacodynamic functions: a multiparameter approach to the design of antibiotic treatment regimens.Impact of high-inoculum Staphylococcus aureus on the activities of nafcillin, vancomycin, linezolid, and daptomycin, alone and in combination with gentamicin, in an in vitro pharmacodynamic model.Daptomycin: pharmacology and clinical use.Protein binding: do we ever learn?Staphylococcus aureus inactivates daptomycin by releasing membrane phospholipids.Daptomycin Pharmacokinetics and Pharmacodynamics in Septic and Critically Ill Patients.Efficacy of novel rifamycin derivatives against rifamycin-sensitive and -resistant Staphylococcus aureus isolates in murine models of infection
P2860
Q28476705-A6CFCE26-E473-4284-82B3-C316F0A392DEQ28478851-DCF5CD80-E020-46F6-B8F0-B4538A5E09CBQ33239640-DD7B2B6E-CCE5-4B33-98CF-4E7C7BB6C46EQ33518268-B35F1291-F309-4A10-9BFD-A4494377DF8EQ33767602-6EE6EEA2-BFC8-4705-96A3-288F2EB25A39Q33883648-D24F8EFF-B079-4EFA-91AE-29E3383C75BAQ34151060-1908F91C-FE2B-4FFF-9568-D6678A48E403Q34228214-EACB7BEC-B3A1-43BC-B8A8-D4144E5758B6Q34737743-870A0E1C-9AF6-46E0-91B7-E531D530FAFBQ34926950-DFBD35BB-0BBC-42AF-BEF3-F58875CC42ACQ34937444-349A5C21-9BAB-4E03-8C4D-3AC14633497EQ35005549-70B4A006-A775-48C0-A3B2-A84106B655C0Q35223557-29003353-4083-4579-BD5F-5A6AE17A403FQ35242592-034B9AC6-57C0-4D6F-980B-C1248BB0C4A5Q35637066-99A83A77-1817-4610-B16A-F433DE75BE66Q35759049-B0EE1BB0-A0B6-4246-9D8F-D04DE7E7986FQ35848781-B0046ED0-8CB6-4424-B43A-676D532D74BDQ35912780-A2527FAC-3C68-4D67-966A-94B365CCC286Q35925535-DDDD6B2C-68D6-43D9-9C30-03EBA4C8EFABQ35941248-E966C508-EE56-4F3D-A548-8E2EB491EA75Q35941476-BD822B39-E16E-464F-8A0C-4C2DFABBC766Q36075986-A0A63C95-85AF-4132-8183-D4B8AA57C5D6Q36150606-2A97080E-0533-45E0-8F04-5AA36F969CF4Q36521880-D7E20D8A-C202-499E-B1F6-ABBFA9093382Q36558512-066B30DB-8A27-4553-9965-8430238C4286Q36644902-5B147727-9AD4-4471-8C4E-CC96820B30EDQ36667227-89884A7A-3E27-44F0-BBB5-0A0605C104FAQ36670451-1AAF1632-1A4D-44AA-B33D-9AF220470BCEQ36879791-83D92A4C-87EE-463E-87C1-F51E265BCF43Q36972980-E1BCF047-9869-4BEA-BCA6-A5E6119951C9Q37149078-A7AB22BA-9F3D-49C5-B3F0-99B7401A544EQ37258898-B0F6BF54-E92E-4580-B19A-C9C655E04A28Q37319460-2405AF2C-CA65-4146-991A-C2E15E2E592BQ37568933-FBC120CD-49E6-409A-9363-7FB4B2F4AC3DQ37625071-ED6A2878-A03D-42D7-A5E9-B745C943546EQ37693931-9B7AE179-770D-4848-B2D9-06CE001A4FC9Q37871252-98E800A7-357B-439F-943F-DB7A8D10E0B7Q38404983-A6781269-C199-4E76-B5C2-E22D4394CFE4Q38895642-353C987E-479F-4C55-925E-60BC295B5E6DQ39078400-54601775-2743-4525-9A24-C61C809E4117
P2860
Pharmacodynamics of daptomycin in a murine thigh model of Staphylococcus aureus infection.
description
2001 nî lūn-bûn
@nan
2001 թուականի Մարտին հրատարակուած գիտական յօդուած
@hyw
2001 թվականի մարտին հրատարակված գիտական հոդված
@hy
2001年の論文
@ja
2001年論文
@yue
2001年論文
@zh-hant
2001年論文
@zh-hk
2001年論文
@zh-mo
2001年論文
@zh-tw
2001年论文
@wuu
name
Pharmacodynamics of daptomycin ...... aphylococcus aureus infection.
@ast
Pharmacodynamics of daptomycin ...... aphylococcus aureus infection.
@en
type
label
Pharmacodynamics of daptomycin ...... aphylococcus aureus infection.
@ast
Pharmacodynamics of daptomycin ...... aphylococcus aureus infection.
@en
prefLabel
Pharmacodynamics of daptomycin ...... aphylococcus aureus infection.
@ast
Pharmacodynamics of daptomycin ...... aphylococcus aureus infection.
@en
P2093
P2860
P1476
Pharmacodynamics of daptomycin ...... aphylococcus aureus infection.
@en
P2093
P2860
P304
P356
10.1128/AAC.45.3.845-851.2001
P407
P577
2001-03-01T00:00:00Z